Detalhe da pesquisa
1.
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
Breast Cancer Res
; 21(1): 108, 2019 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31533777
2.
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial.
EClinicalMedicine
; 71: 102520, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38638399
3.
Observational study of HR+/HER2- metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS).
Clin Transl Oncol
; 25(10): 2950-2959, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37029241
4.
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Neuro Oncol
; 25(1): 157-166, 2023 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35639825
5.
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
Breast
; 54: 286-292, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33242755